Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines
- 1 June 1988
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 114 (3), 306-308
- https://doi.org/10.1007/bf00405839
Abstract
The antiproliferative effect of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines (CG5, T 47 D, and ZR 75-1 is reported. Both peptides markedly inhibited CG5 cell growth with a maximal inhibition of about 40% as compared with control cells. The antiproliferative effect of somatostatin on T 47 D and ZE 75-1 cells was much less evident. These results suggest that somatostatin is a peptide inhibitory factor for human breast cancer cells. Possible therapeutic implications of these findings are still to be investigated.Keywords
This publication has 18 references indexed in Scilit:
- Combined effects of Buserelin, estradiol and Tamoxifen on the growth of MCF-7 human breast cancer cells in vitroBiochemical and Biophysical Research Communications, 1986
- THE SENSITIVITY OF GROWTH HORMONE AND PROLACTIN SECRETION TO THE SOMATOSTATIN ANALOGUE SMS 201–995 IN PATIENTS WITH PROLACTINOMAS AND ACROMEGALYClinical Endocrinology, 1986
- Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneous administrationActa Endocrinologica, 1986
- Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995New England Journal of Medicine, 1985
- Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa‐2 cell lineFEBS Letters, 1985
- Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonistNature, 1985
- Immunocytochemical localization of insulin- and somatostatin-like material in human breast tumorsLife Sciences, 1984
- Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell lineBreast Cancer Research and Treatment, 1983
- EPIDERMAL GROWTH FACTOR, SOMATOSTATIN, AND PSORIASISThe Lancet, 1983
- Physiology and Pharmacology of LHRH and SomatostatinAnnual Review of Pharmacology and Toxicology, 1982